What we do:
Development.
RLS Therapeutics is creating a novel small molecule therapeutic from a proprietary class of compounds to treat a wide range of disease indications.
RLS Therapeutics is creating a novel small molecule therapeutic from a proprietary class of compounds to treat a wide range of disease indications.
RPRx (Recycling Polycarbonyl Redox Therapy) is a novel therapeutic approach to treatment of health disorders caused by disabled mitochondrial function.
Our goal is simple. We strive to decrease risk in drug development while pursuing disease indications that have a profoundly positive effect on human health.
Experienced team of founders and advisory board members.
Initial studies have shown strong efficacy of our molecule class in treating a range of health issues.
Broad range of potential indications increases likelihood of developmental success.
Multiple development inflection points offer opportunity for exit anywhere between early clinical trials and commercialization.
Contact Us: